Related references
Note: Only part of the references are listed.PSMA-PET guided hook-wire localization of nodal metastases in prostate cancer: a targeted approach
Emma Clarebrough et al.
WORLD JOURNAL OF UROLOGY (2019)
The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial
Gerald L. Andriole et al.
JOURNAL OF UROLOGY (2019)
Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis
Seong-Jang Kim et al.
UROLOGIA INTERNATIONALIS (2019)
68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy
Francesco Ceci et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Prospective evaluation of F-18-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial)
Ivan Jambor et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning
Jeremie Calais et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence
Jeremie Calais et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Prospective Evaluation of Ga-68-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging
Ryogo Minamimoto et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
PET Using a GRPR Antagonist Ga-68-RM26 in Healthy Volunteers and Prostate Cancer Patients
Jingjing Zhang et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study
Paul J. Roach et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors
Lucia Baratto et al.
MOLECULAR IMAGING AND BIOLOGY (2018)
68Ga-Labeled PSMA Uptake in Nonprostatic Malignancies: Has the Time Come to Remove PS From PSMA?
Dharmender Malik et al.
CLINICAL NUCLEAR MEDICINE (2018)
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Michael S. Hofman et al.
LANCET ONCOLOGY (2018)
Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker forMetastatic Castration-Resistant Prostate Cancer
Josef J. Fox et al.
JAMA ONCOLOGY (2018)
Imaging of distant metastases of prostate cancer
Filippo Pesapane et al.
MEDICAL ONCOLOGY (2018)
Diagnostic performance of choline PET/CT for the detection of bone metastasis in prostate cancer: A systematic review and meta-analysis
Yu Guo et al.
PLOS ONE (2018)
68Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature
Helle D. Zacho et al.
CLINICAL PHYSIOLOGY AND FUNCTIONAL IMAGING (2018)
The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients
O. C. Guler et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2018)
68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis
Finn E. von Eyben et al.
EUROPEAN UROLOGY FOCUS (2018)
Safety, Dosimetry, and Tumor Detection Ability of 68Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET Imaging
Dorthe Skovgaard et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer
Felix Dietlein et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Theranostic Perspectives in Prostate Cancer with the Gastrin Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results
Berthold A. Nock et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer
D. Porres et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2017)
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
Wolfgang P. Fendler et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour
Christian Uprimny et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
Ali Afshar-Oromieh et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Treatment Outcomes from 68Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET
Louise Emmett et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (18F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer
Tore Bach-Gansmo et al.
JOURNAL OF UROLOGY (2017)
[68Ga]PSMA-HBED-CC Uptake in Osteolytic, Osteoblastic, and Bone Marrow Metastases of Prostate Cancer Patients
Jan-Carlo Janssen et al.
MOLECULAR IMAGING AND BIOLOGY (2017)
Delineating biochemical failure with 68Ga-PSMA-PET following definitive external beam radiation treatment for prostate cancer
George Hruby et al.
RADIOTHERAPY AND ONCOLOGY (2017)
Comparison of 68Ga-HBED-CCPSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology
Constantinos Zamboglou et al.
THERANOSTICS (2017)
Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer
Cordula A. Jilg et al.
THERANOSTICS (2017)
18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer Correlation With Multiparametric MRI and Histopathology
Baris Turkbey et al.
CLINICAL NUCLEAR MEDICINE (2017)
Initial multicentre experience of 68gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited
Amila Siriwardana et al.
BJU INTERNATIONAL (2017)
Clinical impact of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach
Simone Albisinni et al.
BJU INTERNATIONAL (2017)
Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
Jeffrey Goldstein et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2017)
Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer
Oladunni O. Akin-Akintayo et al.
CLINICAL NUCLEAR MEDICINE (2017)
The value of anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT in the diagnosis of recurrent prostate carcinoma: a meta-analysis
Jingyun Ren et al.
ACTA RADIOLOGICA (2016)
Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT
Theodosia Maina et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients
Florian Sterzing et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Extent of disease in recurrent prostate cancer determined by [68Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score
Frederik A. Verburg et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
PET/CT with C-11-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data
Stefano Fanti et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Pilot Comparison of 68Ga-RM2 PET and 68Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer
Ryogo Minamimoto et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Recurrent prostate cancer detection with anti-3-[18F]FACBC PET/CT: comparison with CT
Oluwaseun A. Odewole et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial
Cristina Nanni et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Intra-individual comparison of 68Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer
F. L. Giesel et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
11C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series
Tiziano Graziani et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with 68Ga-PSMA-HBED-CC than with 18F-Fluoroethylcholine PET/CT
David Pfister et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer
Matthias Eiber et al.
EUROPEAN UROLOGY (2016)
Initial Experience of 68Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy
Lars Budaeus et al.
EUROPEAN UROLOGY (2016)
68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer
Annika Herlemann et al.
EUROPEAN UROLOGY (2016)
Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis
Marlon Perera et al.
EUROPEAN UROLOGY (2016)
Diagnostic performance and safety of NMK36 (trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid)-PET/CT in primary prostate cancer: multicenter Phase IIb clinical trial
Hiroyoshi Suzuki et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2016)
68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer
Wolfgang P. Fendler et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy
Isabel Rauscher et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Diagnostic Efficacy of 68Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer
Tobias Maurer et al.
JOURNAL OF UROLOGY (2016)
Biodistribution of [68Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions
Vikas Prasad et al.
MOLECULAR IMAGING AND BIOLOGY (2016)
Integration of 68Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study
Sabrina Dewes et al.
RADIATION ONCOLOGY (2016)
VPAC1 Targeted 64Cu-TP3805 Positron Emission Tomography Imaging of Prostate Cancer: Preliminary Evaluation in Man
Sushil Tripathi et al.
UROLOGY (2016)
68Ga-HBED-CC-PSMA PET/CT Versus Histopathology In Primary Localized Prostate Cancer: A Voxel-Wise Comparison
Constantinos Zamboglou et al.
THERANOSTICS (2016)
Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy
Christina Bluemel et al.
EJNMMI RESEARCH (2016)
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
Neeta Pandit-Taskar et al.
CLINICAL CANCER RESEARCH (2015)
18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse A Comparison to 11C-Choline PET/CT
Cristina Nanni et al.
CLINICAL NUCLEAR MEDICINE (2015)
PSMA PET/CT with Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer
Frederik L. Giesel et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer
Steven P. Rowe et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Dosimetry and First Clinical Evaluation of the New 18F-Radiolabeled Bombesin Analogue BAY 864367 in Patients with Prostate Cancer
Bert-Ram Sah et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Prospective Comparison of F-18-Fluoromethylcholine Versus Ga-68-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy
Joshua J. Morigi et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists
Thomas P. Shakespeare
RADIATION ONCOLOGY (2015)
First-in-human uPAR PET: Imaging of Cancer Aggressiveness
Morten Persson et al.
THERANOSTICS (2015)
[111In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery
Margret Schottelius et al.
EJNMMI RESEARCH (2015)
Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer
Ali Afshar-Oromieh et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
Axel Heidenreich et al.
EUROPEAN UROLOGY (2014)
Annotating STEAP1 Regulation in Prostate Cancer with Zr-89 Immuno-PET
Michael G. Doran et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Anti-1-Amino-3-F-18-Fluorocyclobutane-1-Carboxylic Acid: Physiologic Uptake Patterns, Incidental Findings, and Variants That May Simulate Disease
David M. Schuster et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Preclinical Comparison of (AlF)-F-18- and Ga-68-Labeled Gastrin-Releasing Peptide Receptor Antagonists for PET Imaging of Prostate Cancer
Kristell L. S. Chatalic et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Anti-3-[18F]FACBC Positron Emission Tomography-Computerized Tomography and 111In-Capromab Pendetide Single Photon Emission Computerized Tomography-Computerized Tomography for Recurrent Prostate Carcinoma: Results of a Prospective Clinical Trial
David M. Schuster et al.
JOURNAL OF UROLOGY (2014)
Bone Metastases in Castration-Resistant Prostate Cancer: Associations between Morphologic CT Patterns, Glycolytic Activity, and Androgen Receptor Expression on PET and Overall Survival
Hebert Alberto Vargas et al.
RADIOLOGY (2014)
Localized Prostate Cancer Detection with 18F FACBC PET/CT: Comparison with MR Imaging and Histopathologic Analysis
Baris Turkbey et al.
RADIOLOGY (2014)
Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men
Gesche Wieser et al.
THERANOSTICS (2014)
Value of Fused 18F-Choline-PET/MRI to Evaluate Prostate Cancer Relapse in Patients Showing Biochemical Recurrence after EBRT: Preliminary Results
Arnoldo Piccardo et al.
BIOMED RESEARCH INTERNATIONAL (2014)
In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548
Esa Kahkonen et al.
CLINICAL CANCER RESEARCH (2013)
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2013)
11C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy
Francesco Ceci et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer
Dana E. Rathkopf et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Plasma Pharmacokinetics, Whole-Body Distribution, Metabolism, and Radiation Dosimetry of 68Ga Bombesin Antagonist BAY 86-7548 in Healthy Men
Anne Roivainen et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Targeting GRPR in urological cancers -from basic research to clinical application
Rosalba Mansi et al.
NATURE REVIEWS UROLOGY (2013)
First 18F-labeled ligand for PET imaging of uPAR: In vivo studies in human prostate cancer xenografts
Morten Persson et al.
NUCLEAR MEDICINE AND BIOLOGY (2013)
The detection of disease relapse after radical treatment for prostate cancer: is anti-3-18F-FACBC PET/CT a promising option?
Cristina Nanni et al.
NUCLEAR MEDICINE COMMUNICATIONS (2013)
Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer
Jan D. Soyka et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
The Timing of Salvage Radiotherapy After Radical Prostatectomy: A Systematic Review
Christopher R. King
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Phase I clinical study of NMK36: a new PET tracer with the synthetic amino acid analogue anti-[18F]FACBC
Yuji Asano et al.
ANNALS OF NUCLEAR MEDICINE (2011)
F-18-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging
Michael McCarthy et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Prostate Cancer: PET with F-18-FDG, F-18- or C-11-Acetate, and F-18- or C-11-Choline
Hossein Jadvar
JOURNAL OF NUCLEAR MEDICINE (2011)
Pharmacokinetic Assessment of the Uptake of 16β-18F-Fluoro-5α-Dihydrotestosterone (FDHT) in Prostate Tumors as Measured by PET
Bradley J. Beattie et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Evaluation of a 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid-Conjugated Bombesin-Based Radioantagonist for the Labeling with Single-Photon Emission Computed Tomography, Positron Emission Tomography, and Therapeutic Radionuclides
Rosalba Mansi et al.
CLINICAL CANCER RESEARCH (2009)
Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis
Sebastian Mannweiler et al.
PATHOLOGY & ONCOLOGY RESEARCH (2009)
The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer:: a meta-analysis
A. M. Hovels et al.
CLINICAL RADIOLOGY (2008)
Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer
Morten G. Rasch et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Bombesin receptor antagonists may be preferable to agonists for tumor targeting
Renzo Cescato et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis
Shahrokh F. Shariat et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse:: experience in 100 consecutive patients
Marino Cimitan et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2006)
Positron tomographic assessment of androgen receptors in prostatic carcinoma
F Dehdashti et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2005)
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
A Ghosh et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2004)
Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer
DB Sodee et al.
UROLOGY (2000)
Share Paper
